Drug news
NICE recommends Brintellix (vortioxetine) as a third-line treatment for major depressive episodes- Takeda/Lundbeck
In final guidance, NICE recommends Brintellix (vortioxetine), from Takeda/Lundbeck, be made available as a third-line treatment for major depressive episodes. Vortioxetine should be considered as a treatment option for adults whose condition has responded inadequately to two antidepressants within the current episode.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.